ECU
FOLD

Eisler Capital (US)’s Amicus Therapeutics FOLD Stock Holding History

Eisler Capital (US)’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-83,110
Closed -$824K – 539
2024
Q2 		$824K Buy
83,110
+22,727
+38% +$233K 0.01% 498
2024
Q1 		$711K Buy
+60,383
New +$772K 0.02% 443

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Eisler Capital (US)'s FOLD Position: Q3 2024 in Review

Eisler Capital (US) sold out of Amicus Therapeutics (FOLD) in Q3 2024, closing a stake of 83,110 shares — an estimated $824K sold.

Eisler Capital (US) first reported a position in FOLD in Q1 2024 and held it in 2 quarters. The position peaked at $824K in Q2 2024. 293 funds tracked by Wall St. Rank hold FOLD as of Q3 2024.

  • Eisler Capital (US) reported no remaining Amicus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Eisler Capital (US) sold 83,110 Amicus Therapeutics shares in Q3 2024, an estimated $824K.
  • Eisler Capital (US) first reported a position in Amicus Therapeutics in Q1 2024 and held it in 2 quarters.
  • Eisler Capital (US)'s Amicus Therapeutics position peaked at $824K in Q2 2024.
  • 293 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2024.

Based on Eisler Capital (US)'s 13F filing for Q3 2024, filed 14 Nov 2024.